Exchange: NYSEArca·Updated 07:58 PM EDT

IJH News

News
all
press releases
DKS Stock Faces Wall Street Downgrades After Record Single-Day Drop – Nike Turnaround Now In Question
DKS stock fell more than 30% in the previous session, marking its biggest single-day plunge on record.
Stocktwits
More News
BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why
BioMarin said that it would acquire Alesta for $275M upfront and up to $215M in development and regulatory milestones to bring ALE1 into its portfolio.
Stocktwits
Everpure Stock Hits Record High – TD Cowen Says Oracle Could Be Its New Hyperscale Customer, Sees Meta Revenue Growth Ahead
TD Cowen raised its price target on Everpure stock to $170 from $100 and maintained a ‘Buy’ rating.
Stocktwits
HIMS Falls 6% After Hours On Q2 Loss— Eyes Oral Testosterone And Peptides Expansion
The telehealth company reported a second-quarter net loss of $86.3 million versus prior-year net income of $42.5 million.
Stocktwits
CELH Stock On Track For Best Day In A Year After Post-Earnings Selloff — What’s Driving The Rally?
The billionaire founder of Rockstar Energy, Russ Savage, called for a leadership overhaul at Celsius.
Stocktwits
DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets
CEO Jeff Tangney said Doximity's AI recorded a 4.8% error rate versus 13.6% for Anthropic's Fable 5.
Stocktwits
Why Is HIMS Stock Down 13% Today?
The U.S. Federal Trade Commission on Wednesday sued the telehealth company over allegations it shared sensitive user health data with advertisers.
Stocktwits
LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value
Bloomberg reported that Curium is discussing a deal that would pay roughly $102 per Lantheus share in cash upfront plus an additional $12.50 per share in contingent value rights.
Stocktwits
Should iShares Core S&P Mid-Cap ETF (IJH) Be on Your Investing Radar?
Style Box ETF report for IJH
Zacks
NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally?
The medical device maker, which develops Tumor Treating Fields (TTFields) therapy for cancer, said Q2 marked its strongest performance to date.
Stocktwits

Advertisement|Remove ads.